Wilson Dialysis is a medicare approved dialysis facility center in Wilson, North Carolina and it has 40 dialysis stations. It is located in Wilson county at 2833 Wooten Blvd., Sw, Wilson, NC, 27893. You can reach out to the office of Wilson Dialysis at (252) 206-1471. This dialysis clinic is managed and/or owned by Davita. Wilson Dialysis has the following ownership type - Profit. It was first certified by medicare in September, 1976. The medicare id for this facility is 342507 and it accepts patients under medicare ESRD program.
| Name | Wilson Dialysis |
|---|---|
| Location | 2833 Wooten Blvd., Sw, Wilson, North Carolina |
| No. of Dialysis Stations | 40 |
| Medicare ID | 342507 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2833 Wooten Blvd., Sw, Wilson, North Carolina, 27893 | |
| (252) 206-1471 | |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| NPI Number | 1033179023 |
| Organization Name | Wilson Dialysis |
| Doing Business As | Dva Renal Healthcare Inc |
| Address | 2833 Wooten Boulevard Sw Wilson, North Carolina, 27893 |
| Phone Number | (252) 206-1471 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 54% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 14% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 32% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 47% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 14% |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 48% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 32% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 43% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 35% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 12% |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 54% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 28% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 12% |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 141 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 25 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 155 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1379 |
| Percentage of adult patients getting regular hemodialysis at the center | 92 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 48 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 394 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 90 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Wilson Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 231 |
| Hypercalcemia patient months | 2087 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 241 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 22 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 166 |
| Patient months included in arterial venous fistula and catheter summaries | 1437 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 70 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 4 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 181 |
| Hospitalization Rate in facility | 160.1 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 235.2 |
| Hospitalization Rate: Lower Confidence Limit | 115.6 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Wilson Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 25.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 34.1 |
| Readmission Rate: Lower Confidence Limit | 17.8 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Wilson Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .61 (As Expected) |
| SIR: Upper Confidence Limit | 1.35 |
| SIR: Lower Confidence Limit | .22 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Wilson Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 170 |
| Transfusion Rate in facility | 40.6 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 67.3 |
| Transfusion Rate: Lower Confidence Limit | 26.1 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Wilson Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 842 |
| Mortality Rate in facility | 16 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.6 |
| Mortality Rate: Lower Confidence Limit | 12.9 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago
Forest Hills Dialysis Location: 1605 Medical Park Drive West, Wilson, North Carolina, 27893 Phone: (252) 291-8417 |
News Archive
NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.
American teens are confident they can invent solutions to some of the world's pressing challenges, such as protecting and restoring the natural environment, but more than half feel unprepared for careers in technology and engineering, the Lemelson-MIT Invention Index has found this year.
"Twenty years after the central government collapsed," Somalia is facing drought, food insecurity and conflict larger in scale than when famine conditions hit the nation in the 1990s, "[a]nd given the world's limited interest in a major intervention, that is not likely to change anytime soon," the New York Times reports in a news analysis on the situation.
Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.
The Patient-Centered Outcomes Research Institute Board of Governors today approved $8.6 million to fund a new study comparing treatment options for people with psoriasis.
› Verified 5 days ago